Observational Prospective Study of Immune Checkpoint Inhibitors for Solid Neoplasms

Recruiting now

Conditions studied: Cancer

In brief

This prospective, multicenter observational study included all patients with solid neoplasms who received treatment with immune checkpoint inhibitors (ICIs) in clinical practice, regardless of tumor type, tumor stage, type of immunotherapy, or treatment lines. This study aimed to assess the use, effectiveness, and safety of ICIs for solid neoplasms in real-world populations, which can provide insights into clinical decisions associated with the use of ICIs for the treatment of cancer patients in the real-world setting.

Key facts

Study ID

NCT04766515

Run by

Fudan University

People needed

6000

Starts

2020-09-01

Expected to finish

2027-08-30

Last updated by the study team

2026-06-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age at least 18 years.
• Pathologically confirmed diagnosis of a solid tumor cancer.
• Patients receiving treatment with immune checkpoint inhibitors.
• Ability to understand and willingness to provide the informed consent.

You may not qualify if…

• Age < 18 years.
• Patients with hematological malignancies or solid benign tumors.
• Mental disorders, drug abuse, and social condition that may negatively impact compliance in the opinion of the investigator.

Where it is running

• Fudan University Shanghai Cancer Center — Shanghai, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.